Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT ID: NCT06988605
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2025-07-14
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT03989349
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT03985943
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
NCT03100344
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
NCT04921345
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Treatment with nemolizumab will be determined solely by the participant's physician prior to study enrollment. No additional visits, procedures, or laboratory tests are required outside of routine clinical practice. The visit structure is not defined by the study protocol but is determined by routine medical practice. The visit schedule is intended to facilitate a systematic data assessment according to clinical routine. A sub-study will be completed in Germany and the UK at selected sites in which participants will complete the Peak Pruritus (PP) Numerical Rating Scale (NRS), Average Pruritus (AP) NRS, Sleep Disturbance (SD) NRS, and Pain NRS on a daily basis from Day -1 to Day 14. Data collection will occur remotely, and no clinic visits will be required.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nemolizumab
Participants with moderate-to-severe AD who are receiving nemolizumab (Nemluvio®) in routine clinical practice will be observed for approximately 12 months.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adolescent and adult participants aged \>=12 years with moderate-to-severe AD.
* Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.
Exclusion Criteria
* Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
* Participants who received nemolizumab previously.
* Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Galderma Investigational Site 6399
Watford, Hertfordshire, United Kingdom
Galderma Investigational Site 6400
Kings Lynn, Norfolk, United Kingdom
Galderma Investigational Site 5131
Harrogate, North Yorkshire, United Kingdom
Galderma Investigational Site 6389
Sheffield, South Yorkshire, United Kingdom
Galderma Investigational Site 6395
London, Surrey, United Kingdom
Galderma Investigational Site 6392
Birmingham, West Midlands, United Kingdom
Galderma Investigational Site 6404
Leeds, West Yorkshire, United Kingdom
Galderma Investigational Site 6397
York, Yorkshire, United Kingdom
Galderma Investigational Site 6375
Bridgend, , United Kingdom
Galderma Investigational Site 6388
Epsom, , United Kingdom
Galderma Investigational Site 6394
Harrow, , United Kingdom
Galderma Investigational Site 6393
Kingston upon Thames, , United Kingdom
Galderma Investigational Site 6415
Liverpool, , United Kingdom
Galderma Investigational Site 5210
London, , United Kingdom
Galderma Investigational Site 6368
London, , United Kingdom
Galderma Investigational Site 6396
Manchester, , United Kingdom
Galderma Investigational Site 6402
Metropolitan Borough of Wirral, , United Kingdom
Galderma Investigational Site 5431
Redhill, , United Kingdom
Galderma Investigational Site 6403
Sandbach, , United Kingdom
Galderma Investigational Site 5989
Swansea, , United Kingdom
Galderma Investigational Site 5944
Wolverhampton, , United Kingdom
Galderma Investigational Site - 8893
Birmingham, Alabama, United States
Galdrma Investigational Site - 7077
Phoenix, Arizona, United States
Galderma Investigational Site 7060
Phoenix, Arizona, United States
Galderma Investigational Site - 8535
Phoenix, Arizona, United States
Galderma Investigational Site - 7067
Tucson, Arizona, United States
Galderma Investigational Site - 7074
Corona, California, United States
Galderma Investigational Site 6836
Fountain Valley, California, United States
Galderma Investigational Site 8224
Fremont, California, United States
Galderma Investigational Site 7100
Irvine, California, United States
Galderma Investigational Site 7099
Los Angeles, California, United States
Galderma Investigational Site 8553
Newport Beach, California, United States
Galderma Investigational Site 6836
San Francisco, California, United States
Galderma Investigational Site
Santa Monica, California, United States
Galderma Investigational Site 7107
Thousand Oaks, California, United States
Galderma Investigational Site 7061
Castle Rock, Colorado, United States
Galderma Investigational Site 7059
Fairfield, Connecticut, United States
Galderma Investigational Site 7105
Coral Gables, Florida, United States
Galderma Investigational Site 7063
Cutler Bay, Florida, United States
Galderma Investigational Site 7101
Jupiter, Florida, United States
Galderma Investigational Site 7021
Miami, Florida, United States
Galderma Investigational Site 7084
Miami, Florida, United States
Galderma Investigational Site 7078
Miami, Florida, United States
Galderma Investigational Site 7070
North Miami Beach, Florida, United States
Galderma Investigational Site 7090
St. Petersburg, Florida, United States
Galderma Investigational Site 7054
Tampa, Florida, United States
Galderma Investigational Site 7054
Tampa, Florida, United States
Galderma Investigational Site 7091
Tampa, Florida, United States
Galderma Investigational Site 7058
Chicago, Illinois, United States
Galderma Investigational Site 8142
Indianapolis, Indiana, United States
Galderma Investigational Site 7083
West Lafayette, Indiana, United States
Galderma Investigational Site 7098
Columbia, Maryland, United States
Galderma Investigational Site 8012
Glenn Dale, Maryland, United States
Galderma Investigational Site 7068
Rockville, Maryland, United States
Galderma Investigational Site 7065
Brighton, Massachusetts, United States
Galderma Investigationa Site 7104
Milford, Massachusetts, United States
Galderma Investigational Site 7066
Auburn Hills, Michigan, United States
Galderma Investigational Site 7071
Caledonia, Michigan, United States
Galderma Investigational Site 7108
Grandville, Michigan, United States
Galderma Investigational Site 7072
Troy, Michigan, United States
Galderma Investigational Site 7057
Lee's Summit, Missouri, United States
Galderma Investigational Site 7076
St Louis, Missouri, United States
Galderma Investigational Site 8848
Las Vegas, Nevada, United States
Galderma Investigational Site 7055
Portsmouth, New Hampshire, United States
Galderma Investigational Site - Site 7080
Auburn, New York, United States
Galderma Investigational Site # 7052
East Syracuse, New York, United States
Galderma Investigational Site - 8282
Mount Kisco, New York, United States
Galderma Investigational Site - 7051
New York, New York, United States
Galderma Investigational Site 7109
New York, New York, United States
Galderma Investigational Site 8279
New York, New York, United States
Galderma Investigational Site 7081
Dayton, Ohio, United States
Galderma Investigational Site 7073
Gresham, Oregon, United States
Galderma Investigational Site 8559
Philadelphia, Pennsylvania, United States
Galderma Investigational Site 7103
Philadelphia, Pennsylvania, United States
Galderma Investigational Site 7106
Bluffton, South Carolina, United States
Galderma Investigational Site 7082
Cedar Park, Texas, United States
Galderma Investigational Site 8238
Dallas, Texas, United States
Galderma Investigational Site 7062
Edinburg, Texas, United States
Galderma Investigational Site 7088
Grapevine, Texas, United States
Galderma Investigational Site 7102
Houston, Texas, United States
Galderma Investigational Site 7069
Sugar Land, Texas, United States
Galderma Investigational Site 8618
Waco, Texas, United States
Galderma Investigational Site 7085
Bountiful, Utah, United States
Galderma Investigational Site 7079
Vienna, Virginia, United States
Galderma Investigational Site 6374
Karlsruhe, Baden-Wurttemberg, Germany
Galderma Investigational Site 6412
Langenau, Baden-Wurttemberg, Germany
Galderma Investigational Site 6416
Augsburg, Bavaria, Germany
Galderma Investigational Site 6369
Erlangen, Bavaria, Germany
Galderma Investigational Site 6417
Regensburg, Bavaria, Germany
Galderma Investigational Site 6419
Remscheid, North Rhine-Westphalia, Germany
Galderma Investigational Site 6387
Ahaus, , Germany
Galderma Investigational Site 6383
Augsburg, , Germany
Galderma Investigational Site 6385
Berlin, , Germany
Galderma Investigative Site 6172
Berlin, , Germany
Galderma Investigational Site 6366
Berlin, , Germany
Galderma Investigational Site 6398
Bernau bei Berlin, , Germany
Galderma Investigational Site 6386
Bielefeld, , Germany
Galderma Investigational Site 6066
Buxtehude, , Germany
Galderma Investigational Site 6414
Gladbeck, , Germany
Galderma Investigational Site 6418
Großenhain, , Germany
Galderma Investigational Site 6370
Haslach im Kinzigtal, , Germany
Galderma Investigational Site 6420
Hersbruck, , Germany
Galderma Investigational Site 6384
Koblenz, , Germany
Galderma Investigational Site 6013
Lübeck, , Germany
Galderma Investigational Site 6373
Mainz, , Germany
Galderma Investigational Site 6371
Oberursel, , Germany
Galderma Investigational Site 6411
Oranienburg, , Germany
Galderma Investigational Site 6390
Pforzheim, , Germany
Galderma Investigational Site 6372
Quedlinburg, , Germany
Galderma Investigational Site 5408
London, Hampshire, United Kingdom
Galderma Investigational Site 6401
Southampton, Hampshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Clinical Project Manager
Role: primary
Clinical Project Manager
Role: primary
Clinical Project Manager
Role: primary
Clinical Project Manager
Role: primary
Clinical Project Manager
Role: primary
Clinical Project Manager
Role: primary
Clinial Project Manager
Role: primary
Clinical Project Manager
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPR207806
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.